The peptidylprolyl cis–trans isomerase NIMA-interacting 1 (Pin1) has been considered to be a novel biomarker for the stratification of TNBC patients for treatment, in order to improve the management of poor outcome of cancer. This evidence concerns the gene PIN1 and cancer.